Selected article for: "acute respiratory and lung liver"
Author: Swayne, Leigh Anne; Johnstone, Scott R.; Ng, Chen Seng; Sanchez-Arias, Juan C.; Good, Miranda E.; Penuela, Silvia; Lohman, Alexander W.; Wolpe, Abigail G.; Laubach, Victor E.; Koval, Michael; Isakson, Brant E.
Title: Consideration of Pannexin 1 channels in COVID-19 pathology and treatment
  • Cord-id: 8phped3q
  • Document date: 2020_7_1
    • ID: 8phped3q
    Snippet: Pannexin1 (PANX1) is a ubiquitously expressed, channel-forming protein found in a number of tissues thoughout the body (e.g. lung, vasculature, liver, central nervous system, immune system) that is important in many key physiological and immune responses. PANX1 channels passively flux ATP (predominantly), multiple metabolites, and likely other small anions. PANX1 channels regulate inflammation and host responses to several pathogens, including viruses. While there is currently no evidence sugges
    Document: Pannexin1 (PANX1) is a ubiquitously expressed, channel-forming protein found in a number of tissues thoughout the body (e.g. lung, vasculature, liver, central nervous system, immune system) that is important in many key physiological and immune responses. PANX1 channels passively flux ATP (predominantly), multiple metabolites, and likely other small anions. PANX1 channels regulate inflammation and host responses to several pathogens, including viruses. While there is currently no evidence suggesting novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and PANX1 directly interact, there is an urgent need for therapeutic strategies, especially those targeting the hyper-inflammation and cytokine storm that occurs in severe cases of COVID-19. Here we argue that PANX1, and drugs known to target PANX1 (including the FDA-approved drug probenecid), should be the focus of further investigation in the context of SARS-CoV-2 infection and its associated pathology in COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and lung epithelium: 1, 2
    • ace inhibitor and lung infection: 1
    • acid chain and active form: 1, 2
    • acid chain and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • acid chain and lung infection: 1, 2
    • active form and acute ards respiratory distress syndrome: 1
    • active form and adaptive immune response: 1, 2, 3
    • active form and lung endothelial: 1
    • active form and lung epithelium: 1
    • active form and lung infection: 1, 2
    • active form and lung viral infection: 1
    • acute ards respiratory distress syndrome and lung endothelium: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and lung epithelium: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute ards respiratory distress syndrome and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung microvasculature: 1, 2
    • acute ards respiratory distress syndrome and lung vascular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung vascular inflammation: 1, 2, 3
    • acute ards respiratory distress syndrome and lung viral infection: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome and macrophage cell line: 1